" class="no-js "lang="en-US"> Biostage - Medtech Alert
Tuesday, April 22, 2025
Biostage | Pharmtech Focus

Biostage

About Biostage

Biostage

Biostage is a clinical-stage biotech company that uses cell therapy to regenerate organs inside the human body to treat cancer, trauma and birth defects. We have performed the world’s first regeneration of an esophagus in a human cancer patient. This surgery was performed at Mayo Clinic and was published in August 2021.

Biostage has eight issued U.S. patents, two issued China patents, two orphan-drug designations (which provide seven years of market exclusivity in addition to any patents), and the possibility of two Priority Review Vouchers from the FDA.

Biostage’s current goals include raising capital, uplisting from the OTC bulletin board to NASDAQ and beginning its clinical trial for patients requiring short-segment esophageal replacement in adults.

Related Story

Biostage Announces Appointment of New Chief Financial Officer

August 9 2022

Biostage, Inc. (OTCQB: BSTG) (“Biostage” or the “Company”), a cell-therapy biotechnology company with successful first-in-human experience in […]